Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
Follow TCRT
Alaunos Therapeutics, Inc. (TCRT) Altman Z-score
Alaunos Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −436.02, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −436.02 | 33.93 |
| FY2024 | −469.95 | (307.18) |
| FY2023 | −162.77 | (145.81) |
| FY2022 | −16.97 | (6.44) |
| FY2021 | −10.53 | (18.24) |
| FY2018 | 7.71 | 16.29 |
| FY2017 | −8.58 | 1.86 |
| FY2016 | −10.44 | (13.88) |
| FY2015 | 3.44 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.40 | — | 0.48 | |
| Retained earnings / total assets | (311.74) | — | −436.44 | |
| EBIT / total assets | (1.42) | — | −4.70 | |
| Market value of equity / total liabilities | 7.74 | — | 4.64 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −436.02 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1020.47 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EVGN Evogene Ltd. compare | −20.5× |
| LEXX Lexaria Bioscience Corp. compare | −23.9× |
| SYBX Synlogic, Inc. compare | −35.8× |
| TRAW Traws Pharma, Inc. compare | −89.5× |
| TCRT Alaunos Therapeutics, Inc. | −436× |
| ENVB Enveric Biosciences, Inc. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets